

## What is MINT ?

---

### Myositis Interstitial Lung Disease Nintedanib Trial

Have you been diagnosed with pulmonary fibrosis (Interstitial Lung Disease, (ILD)) and have myositis (polymyositis, dermatomyositis, or anti-synthetase syndrome) or have a positive myositis autoantibodies?

If so, you may be able to participate in a research study to understand the role of anti-fibrotic drugs in myositis associated ILD as well as advanced ILD and myositis research

The MINT trial is a research study using the drug, Nintedanib (Ofev®), an anti-fibrotic drug approved by the Food and Drug Administration (FDA) for the treatment of various types of ILD

## Contact Us

---

If you or someone you know would like further information regarding this research study, please contact us!

[MINTcc@pitt.edu](mailto:MINTcc@pitt.edu)

412-648-9989

**Coordinating Center:  
University of Pittsburgh,  
Pittsburgh, PA, USA**



**Principal Investigator:**

Rohit Aggarwal

[aggarwalr@upmc.edu](mailto:aggarwalr@upmc.edu)

Rohit Aggarwal, MD, MS, is a Professor of Medicine in the Division of Rheumatology at the University of Pittsburgh. He is the co-director of UPMC Myositis Center and medical director of the UPMC Arthritis and Autoimmunity Center.

**Co-Investigators: Drs. Chester V. Oddis, Daniel Kass, Kevin Gibson**

---

## MINT

**Myositis Interstitial Lung Disease  
Nintedanib Trial**

---

A Remote Clinical Trial for Patients with Interstitial Lung Disease (Pulmonary Fibrosis) Associated with Myositis From Your Home Anywhere in USA

**This novel clinical trial  
requires no visit to the  
study center**

Study Website:  
**Mint.Pitt.Edu**





## Study Purpose

- Myositis is a rare autoimmune disease that causes muscle inflammation often leading to muscle weakness.
- Many patients with myositis develop Interstitial Lung Disease (MA-ILD) or pulmonary fibrosis (lung scarring).
- Very limited treatments are available for MA-ILD
- Nintedanib is an anti-fibrotic drug that has already been approved for use in various types of ILD or pulmonary fibrosis.
- The purpose of this study is to help researchers understand if Nintedanib can be used as an effective and safe treatment for MA-ILD in combination with usual medication.

## Could this study be right for you?

### You must:

- Be 18 years of age or older
  - Live in United States (USA)
- Have been diagnosed with Interstitial Lung Disease (ILD) or Pulmonary fibrosis (scarring of lungs)
- Have been diagnosed with myositis (polymyositis, dermatomyositis, anti-synthetase syndrome, etc)  
OR  
have one of the myositis associated autoantibodies

Contact us to be considered

## What to expect :

- First, you will be evaluated to determine your eligibility for the study
- Eligible participants will be asked to take Nintedanib or a placebo over the course of 12 weeks, followed by Nintedanib for another 12 weeks, along with their usual medications for ILD (pulmonary fibrosis)

### Participants will:

- Take Nintedanib (study drug) or placebo as per the trial
- Have audio-video conferences with study doctor or staff
- Perform home testing, vitals, and complete questionnaires at home, with aid from study staff
- Travel to a location close to home for lung function testing and chest images
- A home nurse will perform blood collections in your home
- All study visits will be done remotely from the convenience of your home using a tablet and equipment provided by the study